Lion TCR Pte. Ltd. is investigating LioCyx, an autologous T cell therapy targeting HBV-related hepatocellular carcinoma (HCC) in post-liver transplantation patients. Given the high recurrence rates of HCC in this population, LioCyx addresses a significant unmet medical need, particularly in Asian markets where HBV is prevalent. The competitive landscape includes traditional therapies and emerging immunotherapies, but LioCyx's unique mechanism may provide a differentiated approach. However, the trial's withdrawal due to manufacturing changes raises concerns regarding the product's development timeline and regulatory pathway, necessitating diligence on manufacturing capabilities and timelines for resubmission.